Latest Assay Stories
SEATTLE, May 9, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb for the discovery of immunological biomarkers in oncology. (Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO) Under the collaboration, Adaptive will use its proprietary immune profiling assay, immunoSEQ, to identify potential biomarkers that may inform about drug response. The immunoSEQ assay uses high throughput...
LEWISVILLE, Texas, May 1, 2013 /PRNewswire/ -- med fusion, Pathologists Bio-Medical Laboratories (PBM) and Theranostics Health will be introducing the first of Theranostics Health's TheraLink(TM) Assays for use in patients with malignant diseases at the upcoming American Society of Clinical Oncology (ASCO) Annual '13 Meeting, held in Chicago, IL from May 30,( )2013 through June 4, 2013. The TheraLink(TM) HER Family Assay for primary, recurrent and metastatic breast cancers provides a...
BD MAX(TM) Cdiff Assay Receives FDA Clearance BALTIMORE, April 9, 2013 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it received FDA clearance to market the BD MAX(TM) Cdiff Assay in the United States. The assay is performed on the fully-automated BD MAX(TM) System and is designed to rapidly and accurately detect the toxin B gene (tcdB), which has been shown to be essential to...
--Automated Multi-Tier ADA Test Combines Screening, Confirmatory and Isotyping Steps in a Single Assay-- SAN DIEGO, April 3, 2013 /PRNewswire/ -- Genalyte, Inc. today announced the launch of its MT-ADA(TM)( )anti-drug antibody (ADA) immunogenicity assay designed to run on the Maverick(TM) Detection System. This test combines screening for the presence of ADAs and the characterization of each detected ADA with a full isotype profile. With minimal required sample preparation and...
microRNA-based diagnostic assays for classifying renal cell tumors and for classifying tumors from patients with cancer of unknown or uncertain primary to be featured in poster session on April 7 PHILADELPHIA and REHOVOT, Israel, April 2, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that two posters related to the Company's microRNA-based diagnostic assays will be featured at the...
-Mokascience, Bucher Biotec and KRD Molecular Technologies will Distribute Maverick System and Genalyte Multiplex Assays in Selected European Territories- SAN DIEGO, March 26, 2013 /PRNewswire/ -- Genalyte, Inc. today announced its Maverick(TM)( )Detection System that simultaneously analyzes multiple antibodies and other proteins from a single small sample is now CE marked in Europe for research use. The company also reported its first European distribution agreements for the...
MADISON, Wis., March 8, 2013 /PRNewswire/ -- Cellular Dynamics International, Inc. (CDI), a leading commercial producer of human induced pluripotent stem cell (iPSC) lines and tissue cells for drug discovery, safety, stem cell banking and cellular therapeutics, today announced scientific presentations at the Society of Toxicology's 52(nd) Annual Meeting (SOT), March 10 to 14 in San Antonio, that demonstrate the expanding utility of CDI's iCell® products on toxicology assay...
ST LOUIS, Mo., March 5, 2013 /PRNewswire/ -- Sigma-Aldrich(®) Corporation (NASDAQ: SIAL) today announced that BioReliance(® )(http://www.bioreliance.com), the biologics and early development services business under SAFC(®) (www.safcglobal.com), has signed an agreement to acquire the colonies required for the Big Blue® transgenic rodent mutation (TRM) assay and to obtain a license to its associated trademark from Agilent Technologies. TRM assays, which measure mutation frequency...
BEDFORD, Mass., Jan. 14, 2013 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the U.S. Food and Drug Administration (FDA) has cleared for marketing its APTIMA Trichomonas vaginalis Assay on the Company's fully-automated PANTHER System. The APTIMA Trichomonas vaginalis Assay,...
CLEVELAND, Jan. 14, 2013 /PRNewswire/ -- ChanTest announced today the capability to perform a bioassay in conformance with current Good Manufacturing Practices (cGMP)*. The in vitro assay involves higher throughput Ussing chamber experiments for measuring inhibition of CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) chloride ion channel short circuit current, a measure of chloride ion secretion. ChanTest passed its first regulatory inspection related to this cGMP...
